DSIP is a synthetic nine-residue peptide whose name comes from early rabbit experiments that increased slow-wave electrical activity in the brain. It later reached small controlled human studies of insomnia and hormone secretion. One repeated-night report described improved sleep and daytime function, while other placebo comparisons found little clinical improvement. Taken together, these reports leave uncertainty about whether a useful sleep benefit can be reproduced and sustained in people.
Overview
The original investigators isolated sleep-associated material from rabbit cerebral venous blood and established the sequence of the active nonapeptide. They then compared synthetic DSIP with related peptides under blinded conditions. That chemical and experimental history matters because “sleep-inducing” names an observation in a particular preparation and animal model. It does not specify which human sleep stages should change or how a patient should feel the next day. Schoenenberger and colleagues, 1978
Molecular profile
Forms and derivatives
Emideltide free base and acetate
Emideltide is another name used for DSIP. An acetate salt is a material form rather than a separately demonstrated sleep mechanism. FDA evaluated free-base and acetate bulk substances together while noting characterization and clinical-data gaps.
The laboratory literature and more recent regulatory documents also use the name emideltide. Free peptide, acetate salts and preparations sold through different routes need their own material descriptions. An identical short name on a product label does not establish that the product matches a preparation studied decades earlier.
Uses and research areas
In the insomnia studies, investigators recorded overnight sleep, measured how quickly people fell asleep and asked about sleep quality and daytime tiredness. Those measurements allowed them to compare electrical sleep-stage changes with the experience of sleeping and functioning during the day. The reports below show why those outcomes need to be read together.
Researchers also tested whether DSIP could suppress ACTH, the pituitary hormone that stimulates the adrenal glands to release cortisol. They measured both hormones after a meal and after a challenge with corticotropin-releasing hormone, CRH. These experiments tested a hormonal response in healthy men, separate from the question of whether people with insomnia slept or felt better.
Mechanism of action
Slow waves and sleep spindles are patterns in an electroencephalogram, a recording of electrical activity across the brain. In the original rabbit comparison, synthetic DSIP increased these patterns after direct administration into a brain ventricle. Related fragments and altered preparations did not reproduce the same response. Comparing the defined preparations connected peptide structure with the observed electrical activity and supplied the reason to investigate its effects further. Original experiment
Bes and colleagues studied 16 patients with chronic insomnia in double-blind, matched parallel groups. Patients spent five nights in the laboratory: one to adjust to the setting, one for baseline sleep recordings, and three after afternoon IV DSIP or placebo. The DSIP group spent a slightly greater proportion of time in bed asleep and took less time to fall asleep, but the effects were weak and could partly reflect changes in the placebo group. Patients did not report better sleep quality.
Raeissi and Audus studied whether DSIP could cross a laboratory model of the blood–brain barrier, made from cells lining small blood vessels in the bovine brain. Peptide crossed the cell layer in both directions. Transport did not level off as the tested concentration increased, and metabolic inhibitors did not reduce it, a pattern consistent with diffusion in this model. The experiment did not measure how much DSIP reaches the human brain after administration outside it. Raeissi and Audus, 1989
Pharmacokinetics
Kato and colleagues used an antibody-based enzyme assay to follow DSIP-related material in plasma after intravenous administration in four anesthetized dogs. The reported mean disappearance half-life was 4.0 ± 0.7 minutes. Observations in one monkey and three rats also showed rapid disappearance, with different estimates. The antibody recognized the peptide’s C-terminal region, meaning the assay signal could not be assumed to represent intact DSIP alone. The half-life therefore describes the disappearance of material recognized by that assay. Kato and colleagues, 1984
The human insomnia trials measured sleep outcomes rather than a validated concentration–time profile. The animal estimates cannot supply a human nasal or subcutaneous half-life, and the duration of an observed behavioral change cannot be used to calculate plasma persistence. No exposure curve is drawn from those mismatched measurements.
Research findings
A positive repeated-night report
Schneider-Helmert studied 14 middle-aged people with chronic insomnia under double-blind, placebo-controlled conditions across seven successive treatment nights. The report described better sleep after initial and repeated DSIP administration, continued improvement on the first placebo night after treatment, and improved daytime alertness and performance. The study’s small sample and sequence of baseline, treatment and post-treatment nights are important when comparing these positive observations with the less favorable controlled studies below. Schneider-Helmert, 1987
Other controlled sleep studies were less favorable
In Monti and colleagues’ four-night crossover experiment, people with insomnia received intravenous DSIP or placebo while investigators recorded sleep stages. Several measures moved in a favorable direction during DSIP nights, but most differences were not significant against placebo or baseline. Significant differences in stage-2 and non-REM time were already present at baseline. Slow-wave sleep and REM sleep were unchanged, and the investigators judged the improvement to have little clinical significance. Monti and colleagues, 1987
Bes and colleagues subsequently studied 16 patients in matched parallel groups during five laboratory nights, with intervention before the final three nights. Sleep efficiency was higher and sleep latency shorter with DSIP, but the effects were weak and could partly reflect an incidental change in the placebo group. Subjective sleep quality did not improve. This is particularly relevant to claims about feeling more rested: a small difference in an instrument-derived sleep measure did not produce a consistent patient-reported benefit. Bes and colleagues, 1992
Endocrine testing did not establish cortisol suppression
Späth-Schwalbe and colleagues tested DSIP during corticotropin-releasing hormone stimulation in healthy men, with five participants in each challenge condition. They also examined meal-related hormone secretion in another ten men. ACTH and cortisol responses after the hormone challenge were almost identical with DSIP and placebo, and the meal-related surge was unaffected. These experiments concern stimulated endocrine responses in separate groups, not the insomnia participants. They do not support using DSIP as a general cortisol-lowering treatment. Späth-Schwalbe and colleagues, 1995
Safety and tolerability
DSIP remains experimental, and this review identified no approved indication for treating sleep disorders. Its small, short studies leave uncommon reactions, repeated-use risks and use during pregnancy or complex illness poorly characterized. FDA’s July 2026 briefing assessment also raised questions about verifying the peptide’s identity and purity, clumping of peptide molecules, and the possibility of immune reactions. Reports from withdrawal-treatment settings described headache, nausea, vertigo and low blood pressure, although the underlying condition made their cause difficult to determine. FDA assessment
The assessment proposed excluding the evaluated emideltide substances from the 503A Bulks List. That proposal is reported as an agency assessment, without treating it as a final committee or rulemaking outcome. The material concern remains clinically relevant: historical intravenous observations do not establish the safety of an unspecified contemporary injectable or another delivery route.
What the research means
The strongest reason for continued scientific interest is the combination of a defined molecule, structure-dependent animal activity and measurable human experiments. The central clinical problem is inconsistency across those human comparisons. A sleep-treatment conclusion should depend on reproducible improvements against placebo, including outcomes patients experience, over a clinically meaningful period. The current set of short, small studies does not supply that level of evidence.
Sleep-stage changes, daytime performance and stimulated hormone release should therefore stay visible as separate outcomes. Reading them together helps explain why a biologically active peptide can have an uncertain therapeutic role without assuming that every favorable observation shares one proven mechanism.
FAQs
Does DSIP reliably increase deep sleep?
DSIP was named after rabbit experiments that increased slow-wave electrical activity in the brain. Human sleep recordings have been less consistent: Monti and colleagues found no increase in slow-wave sleep, and the 1992 study found weak differences in time asleep and time to fall asleep, without better reported sleep quality. A reliable improvement in restorative sleep has not been established.
Why do some insomnia reports sound positive?
The small studies arranged baseline, treatment and placebo nights differently. Schneider-Helmert reported better sleep and daytime function in 14 patients, while other controlled studies found weaker benefits. Some sleep-stage differences in the Monti study were already present before DSIP was given, and the Bes study’s small differences could partly reflect changes in its placebo group. Those details help explain why favorable observations have not produced a consistent treatment result.
Does DSIP lower cortisol?
In the controlled CRH and meal experiments, cortisol and ACTH responses were not meaningfully suppressed. Those stimulated endocrine measurements cannot support a general cortisol-lowering claim.
What is its human half-life?
The primary clearance experiment here studied anesthetized animals and an immunoassay signal. It does not establish an intact-DSIP half-life in people or exposure after a marketed nasal or subcutaneous preparation.
Is DSIP an approved sleep medicine?
DSIP remains experimental. FDA’s 2026 assessment found limited clinical evidence and important material and safety gaps; a proposal about compounding eligibility is distinct from approval of a medicine.
Comparisons and related reading
References
The source annotations identify original experiments separately from FDA’s regulatory safety assessment. Older clinical reports were assessed through their original indexed abstracts where full extraction was unavailable.
The original sequence and comparative rabbit EEG experiments establish the nonapeptide identity and the model in which the delta-activity signal was measured.
A small controlled insomnia report described improved night sleep and daytime function; its repeated-night within-person observations belong beside the less favorable trials.
The crossover study found little clinically meaningful improvement. Significant stage-2/NREM differences were already present at baseline, and slow-wave sleep did not change.
In 16 patients, modest sleep-efficiency and latency differences coexisted with unchanged subjective sleep quality and weak effects that might reflect placebo-group fluctuation.
Separate CRH-challenge and meal experiments did not support ACTH/cortisol suppression in healthy men.
An enzyme immunoassay measured rapid disappearance of DSIP-like material after IV administration in anesthetized animals. This is animal immunoreactivity kinetics, rather than a validated human intact-peptide curve.
DSIP crossed a layer of bovine brain blood-vessel cells in both directions. Transport did not level off over the tested concentrations, a pattern consistent with diffusion in this laboratory model.
The agency assessment identifies peptide-characterization, impurity/aggregation and immunogenicity concerns, limited clinical safety, and the absence of supporting subcutaneous clinical data.
Glossary
- Polysomnography
- An overnight recording of brain activity and other signals used to score sleep and wakefulness.
- Sleep efficiency
- The proportion of time in bed that a participant is scored as asleep.
- Immunoreactivity
- An assay signal from material recognized by an antibody; it may not distinguish every intact peptide from related material.
- ACTH
- A pituitary hormone that stimulates adrenal cortisol production.
- CRH
- A hypothalamic signal used experimentally to stimulate the ACTH–cortisol system.